CYPROHEPTADINE- cyproheptadine hydrochloride syrup Chartwell RX, LLC

Cyproheptadine Hydrochloride Syrup

(Cyproheptadine Hydrochloride Oral Solution, USP)

2 mg/5 mL


Rx Only

DESCRIPTION

Each 5 mL (one teaspoonful) contains: cyproheptadine hydrochloride 2 mg

Inactive ingredients: alcohol 5% (v/v), citric acid, D&C Yellow #10, butylated hydroxyanisole, peppermint flavor, sucralose, propylene glycol, purified water, sodium citrate, sorbic acid (0.1%, as preservative).

Cyproheptadine Hydrochloride is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.88, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(*5H*-Dibenzo [*a*,*d*]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C ₂₁H ₂₁N • HCl and the structural formula of the anhydrous salt is:



CLINICAL PHARMACOLOGY

Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.

Pharmacokinetics and Metabolism:

After a single 4 mg oral dose of ¹⁴C-labeled cyproheptadine hydrochloride in normal subjects, given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to

less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine syrup. The principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

INDICATIONS AND USAGE

Perennial and seasonal allergic rhinitis

Vasomotor rhinitis

Allergic conjunctivitis due to inhalant allergens and foods

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

Amelioration of allergic reactions to blood or plasma

Cold urticaria

Dermatographism

As therapy for anaphylactic reactions *adjunctive* to epinephrine and other standard measures after the acute manifestations have been controlled.

CONTRAINDICATIONS

Newborn or Premature Infants: This drug should *not* be used in newborn or premature infants.

Nursing Mothers: Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Other Conditions:

Hypersensitivity to cyproheptadine and other drugs of similar chemical structure

Monoamine oxidase inhibitor therapy (see Drug Interactions)

Angle-closure glaucoma

Stenosing peptic ulcer

Symptomatic prostatic hypertrophy

Bladder neck obstruction

Pyloroduodenal obstruction

Elderly, debilitated patients

WARNINGS

Children: Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions and death.

Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.

CNS Depressants: Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

Activities Requiring Mental Alertness: Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.

PRECAUTIONS

General:

Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with:

History of bronchial asthma

Increased intraocular pressure

Hyperthyroidism

Cardiovascular disease

Hypertension

Information for Patients:

Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

Drug Interactions:

MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term carcinogenic studies have not been done with cyproheptadine. Cyproheptadine had no effect on fertility in a two-litter study in rats or a two-generation study in mice at about 10 times the human dose. Cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts *in vitro*; high doses (10-4M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.

Pregnancy:

Pregnancy Category B. Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by

intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see CONTRAINDICATIONS).

Pediatric Use:

Safety and effectiveness in pediatric patients below the age of two years have not been established. (See CONTRAINDICATIONS, Newborn or Premature Infants, and WARNINGS, Children.)

ADVERSE REACTIONS

Adverse reactions which have been reported with the use of antihistamines are as follows:

Central Nervous System: Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness.

Integumentary: Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity.

Special Senses: Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus.

Cardiovascular: Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock.

Hematologic: Hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia.

Digestive System: Dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice.

Genitourinary: Urinary frequency, difficult urination, urinary retention, early menses.

Respiratory: Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

Miscellaneous: Fatigue, chills, headache, increased appetite/weight gain.

OVERDOSAGE

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.

If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac.

If the patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or $\frac{1}{2}$ isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children.

When life-threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content.

Stimulants should *not* be used. Vasopressors may be used to treat hypotension.

The oral LD ₅₀ of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

DOSAGE AND ADMINISTRATION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

Although intended primarily for administration to children, the syrup is also used for administration to adults who cannot swallow tablets.

Children: The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m²).

Age 2 to 6 years: The usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.

Age 7 to 14 years: The usual dose is 4 mg (two teaspoonsful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.

Adults: The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (two teaspoonsful) three times a day and adjusted according to the size and response of the patient.

HOW SUPPLIED

Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution USP) 2 mg/5 mL in a yellow, peppermint-flavored vehicle is supplied in a 473 mL (16 fl oz) container (NDC 62135-949-47) and in a 946 mL (32 fl oz) container (NDC 62135-949-47).

Store at 20° to 25°C (68° to 77°F) excursion permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

Manufactured for:

Chartwell RX, LLC.

Congers, NY 10920

L70984

Rev. 07/2022

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

CYPROHEPTADINE-HCL - 473 mL - NDC 62135-949-47 - LABEL

NDC 62135-949-47 Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP)	Each 5 ml (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg, Alcohol 5%, Sorbic Acid 0.1 % added as preservative. Usual Dosage: Should be individualized. See package insert. Store at 20° to 25°C (68° to 77°F) excursion permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure. Keep this and all medications out of the reach of children. Manufactured by: Chartwell Pharmaceuticals Carmel, LLC. Carmel, NY 10512 Manufactured for: Chartwell RX, LLC Congers, NY 10920 GTIN 00362135949471 L70982 REV. 01 07/22 Matufactured for: Chartwell RX, LLC Congers, NY 10920	
2 mg/5 mL Sugar Free THIS CONTAINER IS NOT INTENDED FOR HOUSEHOLD USE Pharmacist - Dispense in a tight, light-resistant container with	Each 5 ml (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg, Alcohol 5%, Sorbic Acid 0.1 % added a preservative. Usual Dosage: Should be individualized. See package inse Store at 20° to 25°C (68° to 77°F) excursion permitted to 1 30°C (59° to 86°F) [See USP Controlled Room Temperature] Dispense in a tight, light-resistant container as defined in th with a child-resistant closure. Keep this and all medications out of the reach of children. Manufactured by: Chartwell Pharmaceuticals Carmel, LLC. Carmel, NY 10512 Manufactured for: Chartwell RX, LLC Congers, NY 10920 GTIN 00362135949471 L70982 REV.(GTIN 00362135949471 L70982 REV.(No Varnish
child-resistant closure, and appropriate dosage measuring device. Rx Only 473 mL (16 fl oz.) Chartwell Rx	Each 5 ml (one teaspoonful Hydrochloride 2 mg, Alcohol 5 preservative. Usual Dosage: Should be ind Store at 20° to 25°C (68° to 7 30°C (59° to 86°F) [See USP C 30°C (58° to 7 30°C (58° to 7 30°C (58° to 7 30°C (58° to 7 7 Manufactured by: Chartwell F Carmel, NY Manufactured for: Chartwell F Congers, N Congers, N GTIN 00362135949471	

CYPROHEPTADINE-HCL - 946 mL - NDC 62135-949-94 - LABEL

NDC 62135-949-94 Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP)	Ins: Cyproheptadine c: Acid 0.1 % added as ad. See package insert. Insion permitted to 15° to I Room Temperature]. ainer as defined in the USP, ainer as Rev. 01 07/22	
2 mg/5 mL Sugar Free <u>THS CONTAINER IS NOT</u> <u>INTENDED FOR HOUSEHOLD USE</u> Pharmacist - Dispense in a tight, light-resistant container with child-resistant closure, and appropriate dosage measuring device. Rx Only 946 mL (32 fl oz.)	Each 5 ml (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg, Alcohol 5%, Sorbic Acid 0.1 % added as preservative. Usual Dosage: Should be individualized. See package insert. Usual Dosage: Should be individualized. See package insert. Store at 20° to 25°C (68° to 77°F) excursion permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure. Keep this and all medications out of the reach of children. Manufactured by: Chartwell Pharmaceuticals Carmel, LLC. Carmel, NY 10512 Manufactured for: Chartwell RX, LLC Congers, NY 10920 GTIN 00362135949945 LTC GTIN 00362135949945 LTO GTIN 00362135949945 LTO 3 0,00000000000000000000000000000000000	No Varnish
CYPROHEPTADINE cyproheptadine hydrochloride syrup		

Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source) NDC:		NDC:6	:62135-949	
Route of Administration	ORAL					
Active Ingredient/Active	Moiety					
Ingred	Ingredient Name Basis of Stre			igth	Strength	
CYPROHEPTADINE HYDROCHLOI - UNII:2YHB6175DO)	RIDE (UNII: NJ82J0F8QC) (CYPROHEP		CYPROHEPTADINE HYDROCHLORIDE		2 mg in 5 mL	
Inactive Ingredients						
	Ingredient Name			Str	rength	
PEPPERMINT (UNII: V95R5KMY2B)						
ALCOHOL (UNII: 3K9958V90M)						
ANHYDROUS CITRIC ACID (UNII: >	(F417D3PSL)					
D&C YELLOW NO. 10 (UNII: 355W	5USQ3G)					
BUTYLATED HYDROXYANISOLE (UNII: REK4960K2U)					
SUCRALOSE (UNII: 96K6UQ3ZD4)						
SUCRALOSE (UNII: 96K6UQ3ZD4) PROPYLENE GLYCOL (UNII: 6DC90	Q167V3)					
,	Q167V3)					

Ρ	roduct Chara	acteristi	cs				
Color Shape				Sco	ore		
			Size				
FI	avor		PEPPERMINT Imprir		orint Code		
С	ontains						
P	ackaging						
#	ltem Code		Package Description		Marketing Start Date	Marketin Date	
1	NDC:62135-949- 47	473 mL in Product	1 BOTTLE; Type 0: Not a Comb	oination	07/13/2022		
2	NDC:62135-949- 94	946 mL in Product	1 BOTTLE; Type 0: Not a Comb	oination	07/13/2022		
	larketing	Inform	ation				
M		Appl	ication Number or Mono	graph	Marketing Start Date	Marketin Dat	
Μ	Marketing Category		Citation		Date	Date	-

Labeler - Chartwell RX, LLC (079394054)

Revised: 10/2023

Chartwell RX, LLC